Literature DB >> 18292650

Survival of allogeneic hepatocytes transplanted into the thymus.

Nieves Mula1, Francisco J Cubero, Javier Codesal, Socorro de Andrés, Cristina Escudero, Socorro García-Barrutia, Isabel Millán, Rosa M Arahuetes, Paloma Maganto.   

Abstract

BACKGROUND/AIM: Currently, when cell therapy is being considered instead of liver transplantation to treat terminal liver diseases, complete knowledge of the evolution and behavior of ectopically transplanted hepatocytes is a subject of utmost interest in the design of clinical trials. Hepatocytes survive in ectopic locations and have a therapeutic effect in different experimental models. Although it offers remarkable advantages over liver transplantation, hepatocyte transplantation presents several problems, among them the number of cells that can be injected at once and their rejection. Our main objective was to study the survival and functionality of hepatocytes transplanted into the thymus and, secondarily, to test whether the intrathymic transplant could induce any tolerogenic effect.
METHODS: Hepatocytes from F344 rats were transplanted into thymuses of Gunn rats, half of which received a unique dose of cyclosporine A. The recipients were sacrificed at different times. Light microscopy was performed and bilirubin levels were determined in serum and bile. RESULTS/
CONCLUSIONS: Transplanted hepatocytes survive for at least 6 weeks in the thymus of allogeneic animals without immunosuppressive therapy. The work provides interesting data about the behavior of hepatocytes injected into this unique ectopic site and shows that the thymus can be used as a recipient organ for cell therapy. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292650     DOI: 10.1159/000118096

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  1 in total

Review 1.  Mesenchymal stromal cells as supportive cells for hepatocytes.

Authors:  Alejandro Gómez-Aristizábal; Armand Keating; John E Davies
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.